- Home
- DOUG vs ACHV Comparison
DOUG vs ACHV Comparison
Compare DOUG & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- ACHV
- Stock Information
- Founded
- DOUG 1911
- ACHV N/A
- Country
- DOUG United States
- ACHV Canada
- Employees
- DOUG N/A
- ACHV N/A
- Industry
- DOUG Building operators
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DOUG Real Estate
- ACHV Health Care
- Exchange
- DOUG Nasdaq
- ACHV Nasdaq
- Market Cap
- DOUG 166.2M
- ACHV 159.0M
- IPO Year
- DOUG N/A
- ACHV N/A
- Fundamental
- Price
- DOUG $1.83
- ACHV $4.62
- Analyst Decision
- DOUG
- ACHV Strong Buy
- Analyst Count
- DOUG 0
- ACHV 3
- Target Price
- DOUG N/A
- ACHV $14.00
- AVG Volume (30 Days)
- DOUG 640.9K
- ACHV 84.1K
- Earning Date
- DOUG 11-05-2024
- ACHV 11-07-2024
- Dividend Yield
- DOUG N/A
- ACHV N/A
- EPS Growth
- DOUG N/A
- ACHV N/A
- EPS
- DOUG N/A
- ACHV N/A
- Revenue
- DOUG $951,674,000.00
- ACHV N/A
- Revenue This Year
- DOUG $3.85
- ACHV N/A
- Revenue Next Year
- DOUG $17.40
- ACHV N/A
- P/E Ratio
- DOUG N/A
- ACHV N/A
- Revenue Growth
- DOUG N/A
- ACHV N/A
- 52 Week Low
- DOUG $1.00
- ACHV $3.03
- 52 Week High
- DOUG $3.16
- ACHV $5.98
- Technical
- Relative Strength Index (RSI)
- DOUG 51.03
- ACHV 55.36
- Support Level
- DOUG $1.42
- ACHV $4.32
- Resistance Level
- DOUG $2.05
- ACHV $4.57
- Average True Range (ATR)
- DOUG 0.16
- ACHV 0.14
- MACD
- DOUG 0.00
- ACHV 0.04
- Stochastic Oscillator
- DOUG 67.20
- ACHV 85.19
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.